Ocugen, Inc. NASDAQ (OCGN)
5.52$-0.12 -2.13%
At close 04:00 PM
From:
To:
Stock Snapshot
5.64
Prev. Close
5.61
Open
1.10B
Market Cap
Number of Shares
5.24
Day Low
5.67
Day High
5.52
-
P/E Ratio
181.89M
Free Float in %
-0.36
EPS 2021
0.13
Book Value per Share
0.12
Cash Flow per Share
Ocugen, Inc. (OCGN)
Ocugen, Inc. (OCGN) stock rallied over -2.13% intraday to trade at $5.52 per share on NASDAQ. The stock opened with a fall of -0.53% at $5.61 and touched an intraday high of $5.67, rising 0.53% against the last close of $5.64. The stock went to a low of $5.24 during the session.
Recent News
Crypto News
April 22, 2021
Featured
April 22, 2021
Featured
April 22, 2021
Historical Prices
| Date | Open | Close | Adj. Close | Daily High | Daily Low | Volume |
|---|---|---|---|---|---|---|
| 2021-04-21 | $6.65 | $6.50 | $6.50 | $6.76 | $5.83 | 132,554,600 |
| 2021-04-20 | $5.61 | $5.52 | $5.52 | $5.67 | $5.24 | 13,460,700 |
| 2021-04-19 | $5.39 | $5.64 | $5.64 | $5.93 | $5.29 | 12,351,100 |
| 2021-04-16 | $5.92 | $5.78 | $5.78 | $5.99 | $5.51 | 17,410,100 |
| 2021-04-15 | $6.86 | $6.15 | $6.15 | $6.89 | $6.06 | 18,546,800 |
| 2021-04-14 | $6.75 | $6.90 | $6.90 | $7.49 | $6.68 | 32,764,300 |
| 2021-04-13 | $6.84 | $6.71 | $6.71 | $6.98 | $6.55 | 13,071,300 |
| 2021-04-12 | $6.94 | $6.68 | $6.68 | $7.08 | $6.66 | 11,063,500 |
| 2021-04-09 | $6.79 | $6.96 | $6.96 | $7.25 | $6.76 | 18,216,000 |
| 2021-04-08 | $7.07 | $6.91 | $6.91 | $7.33 | $6.65 | 21,545,300 |
| 2021-04-07 | $6.40 | $6.89 | $6.89 | $8.25 | $6.28 | 86,840,500 |
Ocugen, Inc.
Employees
15
15
Sector
Healthcare
Healthcare
Sales or Revenue
40,000
40,000
Industry
Biotechnology
Biotechnology
5Y Sales Change
-
-
Fiscal Year Ends
2020-12-30
2020-12-30
Dr. Shankar Musunuri M.B.A., Ph.D., MBA
Co-Founder, Chairman & CEO
Dr. Uday B. Kompella Ph.D.
Founder & Independent Director
Mr. Sanjay S. Subramanian M.B.A.
Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec.
Ocugen, Inc.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.